New Delhi : Drug major Lupin expects to launch nearly 25 products in the US market in 2016-17 that the company expects to be the key driver for its revenue growth, going forward.
“We expect to launch a good number of products between India and Gavis (US). We are hoping to launch 25 plus products, FDA permitting. So, a good number of launches that we expect for the year,” Lupin CEO Vinita Gupta said in a conference call.
In the current year, apart from the Gavis portfolio, Fortamet and Glumetza, the company expects to launch products like Minastrin and Epzicom.
The Mumbai-based firm expects to go ahead with launches on the dermatology front this year, she added.
“We expect to start seeing launches on the dermatology front this year, and next year, (there will be) certainly good impact from our dermatology pipeline both out of India as well as Somerset,” Gupta said.
“So, I would say in the next two years, a combination of our products in particular semi-exclusive, exclusive plus dermatology pipeline out of India as well as Gavis plus the controlled substances should add very nicely to our revenues as well as profitability.”
Lupin had announced acquisition of Somerset-based Gavis Pharmaceuticals on July 23 last year.